Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
about
Critical appraisal of trastuzumab in treatment of advanced stomach cancerNew advances in targeted gastric cancer treatmentCurrent and emerging therapies in unresectable and recurrent gastric cancerTargeted therapy for advanced gastric cancer: A review of current status and future prospectsSecond-line treatment of metastatic gastric cancer: Current options and future directionsChemotherapy beyond second-line in advanced gastric cancerCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersAdvances in targeted therapies and new promising targets in esophageal cancerTargeting receptor tyrosine kinases in gastric cancerGastric Cancer: New Drugs - New StrategiesEfficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysisFrom molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsSunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Sunitinib-associated pseudothrombocytopenia induced by IgM antibody.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Molecular targeting to treat gastric cancer.Treatment options in patients with metastatic gastric cancer: current status and future perspectivesCurrent status of novel agents in advanced gastroesophageal adenocarcinoma.Targeting metastatic upper gastrointestinal adenocarcinomasTargeting angiogenesis in esophagogastric adenocarcinoma.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel futureTargeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Targeted therapy for esophagogastric cancers: a reviewAntitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.Targeted therapy in gastroesophageal cancers: past, present and future.Targeted therapies in gastric cancer and future perspectives.Molecular targeted therapy for advanced gastric cancerDiscovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.New and emerging combination therapies for esophageal cancer.Targeted therapy in gastric cancer.Targeted therapies for metastatic esophagogastric cancerTargeted therapies in the treatment of gastric cancer.Evolving standards of care in advanced gastric cancer.Second-line chemotherapy for advanced gastric cancer in Korea.Current status of targeted therapies in advanced gastric cancer.
P2860
Q24604411-B01B7232-4B07-41CE-B769-CCCA5BA31D44Q26738548-9DAD6D4C-D161-4B74-9EEC-BDA2E1365F32Q26745453-7F33D96B-FD89-49E0-BDBE-0CB128583772Q26774138-564F2E2B-F53F-4D61-97BB-21301EBF042DQ26778027-D4F5C1B6-85EB-498A-91A8-3EFC8AE36ED4Q26798288-007F61AC-F6E7-43EC-A4AF-9301ABBBB26DQ26801289-9FCD660E-7271-426C-B155-DA4887D3CAA5Q26825957-EB4B0756-832E-40B8-94DC-9F751BD67C23Q27013050-EF47C763-3387-4ADB-9F7F-1A60AA3BCDA6Q27028079-DB03AC2F-EACF-49F9-AF72-10C40E544E63Q28079362-C593D5F8-0EA4-4579-BD4A-E12992CFD04AQ28082921-FB73B434-AFD2-49B3-9583-AFBA9F9CA72FQ28544422-983872A3-C89A-4735-8C10-161ED024B52BQ30313895-8AB43056-60D9-4E17-8991-1A8F4CE39E7EQ33403806-EB840E42-1698-4B7C-9CDB-DD038DD7D84FQ33407676-B1F0465A-C514-47F2-AA29-145932D46987Q33420495-DFE7CFDF-9682-4775-8DA7-EC340AA58726Q33633424-E1552C7F-C69E-44CB-B3AC-0496942AB3DEQ34326593-62EBBE44-32C1-4CF5-96C6-D9C94C13E564Q34661367-8CD61FD4-E7BB-4670-A07A-972088F1AADCQ34962039-A1BC5CD1-C503-4306-AFEF-AC9D510673F1Q35000785-8F488BC0-B8E8-46CF-B4BF-9E3A8D0F353AQ35584958-F72DD2CD-2643-4880-B33A-A80402FD631CQ35640101-49347EFD-2FA5-437E-A74A-8F7EDC284D38Q35863874-CC558694-4A79-4E6B-A2AD-5CBA0CD175C9Q35927364-955A0D32-BECA-4012-892F-60FCD90F7E44Q36039645-1E1D6925-07EA-4DB4-8600-92EAF23BC0CBQ36223964-6722C7E2-FA6C-4055-AEBE-3468B32AB38DQ36280358-2CB01D33-01C1-4B20-9B54-76DD9BB0E3D0Q36294579-B1084436-B69D-492B-82F5-5EFD20504A52Q36471685-840744D6-65BE-4E19-AABB-F93D41A6E651Q36705689-56E77F41-A7EA-4664-AAB0-437843470701Q36799684-D2FB57E7-CF99-4E1B-A17D-90E1F8999C9AQ36996728-8B3DDE7C-57E1-4428-B463-4EC19BE36C11Q37341824-E8C677B6-F584-4F2C-BCC5-799743C5018DQ37836513-7D28940C-1819-478E-99D5-51DFDF591395Q37925131-7DA78594-4993-4C2F-9E31-CC53983A1743Q37960206-F6F2A9FD-02C1-43EF-9138-F159AE9AF3DBQ37992841-D0C9AEB5-ABB4-44E2-A20D-8B859800BF88Q37996448-EA1DB6A1-06C2-4A4A-8652-34BFD6058A0B
P2860
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@ast
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@en
type
label
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@ast
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@en
prefLabel
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@ast
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@en
P2093
P2860
P1476
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
@en
P2093
Alberto Sobrero
Dongrui Ray Lu
Hyun C Chung
Jen-Shi Chen
Jennifer M Tursi
Maria J Lechuga
Narikazu Boku
Shukui Qin
Wai-Tong Ng
P2860
P2888
P304
P356
10.1007/S10637-010-9438-Y
P577
2010-05-12T00:00:00Z
P5875
P6179
1037371356